Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SRNDM-07 is an investigational small interfering RNA (siRNA) therapy being developed by Sirius Therapeutics (also known as Sirius Natural) for the treatment of heart failure. As part of the company's cardiometabolic disease pipeline, SRNDM-07 utilizes siRNA-mediated gene silencing to target an undisclosed molecular pathway involved in the pathogenesis of heart failure. The program leverages Sirius's proprietary delivery technology, which is designed to enable targeted delivery to various tissues, including the liver, adipose, heart, kidney, and central nervous system. SRNDM-07 is currently in the pre-clinical/IND-enabling stage of development.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on SRNDM-07.